Literature DB >> 2899784

Trial of anonymous versus confidential human immunodeficiency virus testing.

L J Fehrs1, D Fleming, L R Foster, R O McAlister, V Fox, S Modesitt, R Conrad.   

Abstract

Before December, 1986, all public human immunodeficiency virus (HIV) testing in Oregon was done confidentially (using names). In December, clients were offered the option of either anonymous or confidential services. As judged by questionnaire responses, the availability of anonymity increased overall demand for testing by 50%: 125% for homosexual/bisexual (gay) men, 56% for female prostitutes, 17% for intravenous drug users, and 32% for other clients. The number of gay clients who had tests increased from a mean of 42 per month during the 4 months before anonymity was available to 108 per month during the 4 months after, whereas, at public sites in Colorado or California and private sites in Oregon, the number of gay clients tested did not increase. Twice as many seropositive persons were identified during the 3 1/2 months after anonymity became available (n = 85) as in the 3 1/2 months before (n = 36). Thus, availability of anonymous HIV testing and counselling drew gay men who had not sought services under a confidential testing system.

Entities:  

Keywords:  Health Care and Public Health; Professional Patient Relationship; Americas; Behavior; Confidential Information; Developed Countries; Developing Countries; Diseases; Ethics; Examinations And Diagnoses; Health Services Administration--changes; Health Services Evaluation; Hiv Infections; Homosexuals; Laboratory Examinations And Diagnoses; Management; North America; Northern America; Oregon; Organization And Administration; Population At Risk; Program Acceptability; Program Evaluation; Programs; Research Methodology; Research Report; Sex Behavior; United States; Viral Diseases

Mesh:

Year:  1988        PMID: 2899784     DOI: 10.1016/s0140-6736(88)92846-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

1.  Name-based reporting of HIV-positive test results as a deterrent to testing.

Authors:  W J Woods; J W Dilley; T Lihatsh; J Sabatino; B Adler; J Rinaldi
Journal:  Am J Public Health       Date:  1999-07       Impact factor: 9.308

Review 2.  Predictors of success in implementing HIV prevention in rural America: a state-level structural factor analysis of HIV prevention targeting men who have sex with men.

Authors:  B R Simon Rosser; Keith J Horvath
Journal:  AIDS Behav       Date:  2007-04-14

3.  The effect of name-based reporting and partner notification on HIV testing in New York State.

Authors:  James M Tesoriero; Haven B Battles; Karyn Heavner; Shu-Yin John Leung; Chris Nemeth; Wendy Pulver; Guthrie S Birkhead
Journal:  Am J Public Health       Date:  2008-04       Impact factor: 9.308

4.  Confidential and anonymous testing.

Authors:  J P Krajeski
Journal:  West J Med       Date:  1990-06

5.  Confidential versus anonymous human immunodeficiency virus antibody testing.

Authors:  R E Hoffman; F C Wolf; R C Wood; C Raevsky; T M Vernon
Journal:  West J Med       Date:  1990-01

6.  Anonymity in testing for HIV antibodies desired option.

Authors:  R Weitz
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

7.  HIV test-seeking before and after the restriction of anonymous testing in North Carolina.

Authors:  I Hertz-Picciotto; L W Lee; C Hoyo
Journal:  Am J Public Health       Date:  1996-10       Impact factor: 9.308

8.  Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rates.

Authors:  Gayatri C Jayaraman; Jutta K Preiksaitis; Bryce Larke
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

9.  Point and counterpoint: patient control of access to data in their electronic health records.

Authors:  Kelly Caine; William M Tierney
Journal:  J Gen Intern Med       Date:  2015-01       Impact factor: 5.128

Review 10.  Patient perspectives of medical confidentiality: a review of the literature.

Authors:  Pamela Sankar; Susan Mora; Jon F Merz; Nora L Jones
Journal:  J Gen Intern Med       Date:  2003-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.